Humacyte Announces JAMA Surgery Publication Highlighting Potential of Human Acellular Vessel™ (HAV™) to Expand Vascular Trauma Reconstruction and Bypass Treatment Options - GuruFocus.com

Value Investing | Market insights and news of the investment gurus. Value investing screens and valuation tools.

-- HAV implanted in nearly 500 patients with more than 1,000 patient-years of follow up to date, for treatment of peripheral arterial disease, arteriovenous access for hemodialysis, and trauma -- I… [+8017 chars]

full article...